

SCIENTIFIC REPORTS



OPEN

Erythropoietin (*EPO*) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes

Alberto Montesano¹, Anna Rita Bonfigli², Maria De Luca³, Paolina Crocco¹, Paolo Garagnani^{4,5}, Elena Marasco⁴, Chiara Pirazzini⁴, Cristina Giuliani⁴, Fabio Romagnoli⁶, Claudio Franceschi^{4,7}, Giuseppe Passarino¹, Roberto Testa⁸, Fabiola Olivieri^{9,10} & Giuseppina Rose¹

Type-2 Diabetes (T2D), diabetic complications, and their clinical risk factors harbor a substantial genetic component but the genetic factors contributing to overall diabetes mortality remain unknown. Here, we examined the association between genetic variants at 21 T2D-susceptibility loci and all-cause mortality in an elderly cohort of 542 Italian diabetic patients who were followed for an average of 12.08 years. Univariate Cox regression analyses detected age, waist-to-hip ratio (WHR), glycosylated haemoglobin (HbA1c), diabetes duration, retinopathy, nephropathy, chronic kidney disease (CKD), and anaemia as predictors of all-cause mortality. When Cox proportional hazards multivariate models adjusted for these factors were run, three *erythropoietin* (*EPO*) genetic variants in linkage disequilibrium (LD) with each other (rs1617640-T/G, rs507392-T/C and rs551238-A/C) were significantly (False Discovery Rate < 0.1) associated with mortality. Haplotype multivariate analysis revealed that patients carrying the G-C-C haplotype have an increased probability of survival, while an opposite effect was observed among subjects carrying the T-T-A haplotype. Our findings provide evidence that the *EPO* gene is an independent predictor of mortality in patients with T2D. Thus, understanding the mechanisms by which the genetic variability of *EPO* affects the mortality of T2D patients may provide potential targets for therapeutic interventions to improve the survival of these patients.

T2D has an estimated prevalence of more than 9% worldwide, with the number of diabetic patients predicted to increase over the next ten years particularly due to the growth of the aging population and the increased incidence of overweight and obesity¹. Patients with T2D have an increased risk of developing microvascular and macrovascular complications, which, in turn, are the major cause of cardiovascular deaths in these individuals². Cancer as well as non-cardiovascular and non-cancer causes have also been reported to increase the risk of mortality in diabetic patients compared to nondiabetic subjects^{3,4}. The underlying root factors of the relationship between diabetes complications and mortality are not fully understood and their identification is vital to improve health outcomes and reduce premature mortality rates of patients. Recently, an observational cohort study reported that modifiable lifestyle habits, such as the quality of food eaten, physical activity, and tobacco

¹Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036, Rende, Italy. ²Scientific Direction, IRCCS INRCA, National Institute, Ancona, Italy. ³Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. ⁴Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy. ⁵Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden. ⁶Diabetology Unit, IRCCS INRCA, National Institute, Ancona, Italy. ⁷IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. ⁸Clinical Laboratory and Molecular Diagnostics, IRCCS INRCA, Ancona, Italy. ⁹Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy. ¹⁰Center of Clinical Pathology and Innovative Therapy, National Institute IRCCS INRCA, Ancona, Italy. Alberto Montesano, Anna Rita Bonfigli, Fabiola Olivieri and Giuseppina Rose contributed equally. Correspondence and requests for materials should be addressed to G.R. (email: pina.rose@unical.it)

Characteristic	Total (N = 542)	Survivors (N = 444)	Non-survivors (N = 98)	P-value*
Age (yrs)	65.8 (8.0)	64.8 (7.8)	70.7 (7.3)	1.86*10 ⁻¹¹
Gender (% men)	297 (54.8)	236 (53.2)	61 (62.2)	0.102
BMI (kg/m ²)	28.9 (4.6)	28.9 (4.5)	29.0 (5.2)	0.756
WHR (mean, SD)	0.93 (0.07)	0.93 (0.07)	0.94 (0.07)	0.069
HOMA-IR (mean, SD)	2.95 (2.85)	2.79 (2.52)	3.69 (3.92)	0.032
Glucose (mean, SD) [mg/dl]	164.5 (48.8)	162.3 (47.9)	174.4 (52.1)	0.026
Insulin (mean, SD)	7.1 (5.6)	6.8 (4.9)	8.4 (8.0)	0.069
Hemoglobin (mean, SD) [mg/dl]	14.3 (1.28)	14.3 (1.62)	14.3 (1.33)	1.000
Anemia (n, %)**	22 (5.0)	11 (11.2)	33 (6.1)	0.019
RBC (mean, SD)	4.72 (0.43)	4.66 (0.52)	4.71 (0.45)	0.200
HbA1c (mean, SD) [%] [mmol/mol]	7.5 (1.3) 57.9 (13.9)	7.4 (1.3) 57.6 (13.9)	7.8 (1.3) 61.4 (13.7)	0.013
Total cholesterol (mean, SD) [mg/dl]	207.2 (37.9)	206.8 (37.2)	207.2 (40.8)	0.923
HDL cholesterol (mean, SD) [mg/dl]	52.3 (14.6)	52.5 (14.2)	51.3 (16.5)	0.505
Diabetes duration (mean, SD) [years]	15.3 (11.3)	14.06 (10.6)	20.9 (12.6)	5.0*10 ⁻⁶
Retinopathy (n, %)	152 (28.0)	111 (25.0)	41 (41.8)	0.001
Nephropathy (n, %)	73 (13.5)	52 (11.7)	21 (21.4)	0.011
Neuropathy (n, %)	101 (18.6)	76 (17.1)	25 (25.5)	0.053
Chronic Kidney Disease (n, %)	20 (3.7)	10 (2.3)	10 (10.2)	1.57*10 ⁻⁴

Table 1. Baseline characteristics of T2D patients stratified according to the occurrence of death during follow-up. SD, standard deviation; BMI, Body Mass Index; WHR, waist-to-hip ratio; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, glycosylated haemoglobin; RBC, Red Blood Cells. *t-test for continuous variables; Chi-square test for categorical variables. **Anaemia was defined in accordance with the World Health Organization (WHO) criteria (hemoglobin levels <13 g/dL in men and <12 g/dL in women).

and alcohol use, are associated with reduced risk for CKD and mortality in middle-aged individuals with T2D⁵, suggesting that lifestyle behavior might in part account for this relationship. However, findings from several other observational studies argue for a more complex link between the main determinants of mortality in diabetic patients^{6–9}. For instance, using data on more than 200,000 adults with T2D and after adjusting for multiple confounding factors, Kontopantelis *et al.*⁸ predicted that U-shaped relationships exist between glycated hemoglobin, blood pressure, total cholesterol, and all-cause mortality in diabetic patients. Consistently, a significant association between increased mortality and low levels of the above mentioned biological factors has also been reported in a large population of very old diabetic subjects (≥ 80 years of age)⁹.

T2D, diabetic complications, and their clinical risk factors have a strong genetic component^{10,11}, which, in turn, might contribute to a higher risk for mortality. In this regard, previous work showed a significant association of three common genetic variants on 9p21, a chromosomal region linked to T2D and cardiovascular disease, with the mortality rate in Dutch diabetic patients¹². Association with all-cause mortality was also reported for a variant at the glutamate-ammonia ligase (GLUL) locus, a marker of increased CHD risk¹³. Furthermore, a genetic risk score that includes 38 common T2D risk variants was found associated with mortality in an ethnic- and body weight-specific manner¹⁴. However, despite these findings, little is still known about the genetic factors that predispose to mortality in T2D patients. To this end, we performed a population-based, prospective cohort analysis to identify genetic risk factors for all-cause mortality in a cohort of central Italian diabetic patients, who were previously tested for genetic associations with T2D and its complications¹⁵.

Results

Baseline phenotypic and clinical characteristics of the entire cohort of diabetic patients and stratified by survivors and non-survivors are shown in Table 1. The mean age of all T2D patients was 65.8 years, and 54.8% of them were men. The population had a mean diabetes duration of 15.3 years (SD 11.4 years) and on average an acceptable to good glycemic control (mean HbA1c 7.5%). At the end of an average follow-up duration of 12.08 years, 98 patients had died (18.1%). Patients who died during the follow-up were older and had significantly higher insulin resistance (HOMA-IR), serum levels of glucose, insulin, HbA1c, and average diabetes duration. Moreover, a significantly higher prevalence of nephropathy, diabetic retinopathy, and CKD characterized the patients who died during the follow-up (Table 1).

Overall survival rates for diabetic patients with higher values of WHR and HbA1c were worse than the other patients (Table 2). Diabetes duration also significantly influenced patient survival, with patients having a longer diabetes duration living shorter than those with shorter diabetes duration. Furthermore, diabetic patients with neuropathy nephropathy, retinopathy, CKD, and anemia lived less than patients without vascular complications (Table 2).

Kaplan–Meier survival analysis showed that the overall survival rate of diabetic patients was also correlated with five single nucleotide polymorphisms (SNPs) located in or near three different genes: rs1617640-T/G, rs507392-T/C, and rs551238-A/C in the *EPO* gene, rs1121980-C/T in the *FTO* gene, and rs1800849-C/T in the *UCP3* gene (see Supplementary Fig. S1 and Table S1). After False Discovery Rate (FDR) correction, association

Variable	HR (95% CI)	P-value
Age	1.11 (1.08–1.14)	<0.001
Gender (men)	1.39 (0.92–2.09)	0.116
BMI*	1.07 (0.72–1.59)	0.750
WHR*	1.51 (1.01–2.26)	0.046
HbA1c*	1.50 (1.01–2.23)	0.045
Anaemia	2.53 (1.35–4.73)	0.004
HOMA-IR*	1.48 (0.99–2.22)	0.056
Insulin*	1.16 (0.77–1.74)	0.489
Glucose*	1.41 (0.95–2.10)	0.087
Diabetes duration (>10yrs)	2.48 (1.51–4.09)	<0.001
Retinopathy	1.94 (1.30–2.90)	0.001
Nephropathy	1.82 (1.12–2.95)	0.015
Neuropathy	1.58 (1.00–2.49)	0.049
Chronic Kidney Disease	3.71 (1.93–7.15)	<0.001

Table 2. Hazard ratios for all-cause mortality for baseline characteristics. BMI, Body Mass Index; WHR, waist-to-hip ratio; HbA1c, glycosylated haemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance. *Sample mean used as a cut-off value.

of *EPO*-variants with survival remained significant ($q < 0.10$; see Supplementary Table S1). Multivariate Cox proportional models were then fitted using age, WHR, HbA1c, diabetes duration, retinopathy, nephropathy, CKD, and anaemia as covariates. Once again, we found that variants in the *EPO* gene remained significantly associated with mortality risk at a nominal level of 0.05. As shown in Fig. 1, patients carrying the minor allele of rs1617640-(G) and rs507392-(C) had a significantly increased chance of survival with HR values of 0.63 (95% CI = 0.40–0.98, P-value = 0.039) and 0.58 (95%CI = 0.37–0.92, P-value = 0.020), respectively. There was a trend for a positive association with survival also for carriers of the minor allele of rs551238-(C) (HR = 0.66, 95%CI = 0.42–1.03, P-value = 0.065).

LD analysis showed a high degree of disequilibrium among the three *EPO* SNPs ($r^2 > 0.97$), meaning that the associations are not independent. As such, haplotype analysis was performed to further explore the relationship between *EPO* variations and diabetes mortality risk. Out of the eight possible haplotypes, two, T-T-A (major allele combination, 67.0%) and G-C-C (minor allele combination, 32.2%), were the most common in our study samples. As shown in Fig. 2, haplotype multivariate survival analysis corroborated the single-locus analyses. While the presence of the T-T-A haplotype was found to decrease the chance of survival, carriers of the G-C-C haplotype showed a significantly increased survival chance with respect to non-carriers (HR = 0.63, 95%CI = 0.41–0.99, P-value = 0.044).

Discussion

Patients with T2D have higher all-cause mortality risk than matched individuals without diabetes^{16,17}. Epidemiological studies have identified several demographic, socioeconomic, and biological independent predictors of mortality in T2D patients^{8,18}, but only a few of them have evaluated the role of genetic factors. In agreement with the current literature, this study identified age, WHR, HbA1c, diabetes duration, retinopathy, nephropathy, CKD, and anaemia as predictors of all-cause mortality. Additionally, after adjusting for the effects of these risk factors, our results showed that three *EPO* genetic variants in high LD (rs1617640-T/G, rs507392-T/C and rs551238-A/C) were associated with all-cause mortality risk in both single-SNP and haplotype-based analyses.

The *EPO* gene encodes erythropoietin, which is a kidney-derived cytokine that plays a major role in promoting erythropoiesis, in particular in response to hypoxic stress¹⁹. However, recent evidence shows that *EPO* is also expressed locally in others tissues and organs, including peripheral endothelial cells, muscle, and insulin-producing cells, where it displays anti-apoptotic, anti-inflammatory, and angiogenic effects due to its ability to activate several transduction signalling pathways^{20–23}. A growing literature argues for a critical role of *EPO* in diabetes and its complications²⁴. For example, Fenjves *et al.* demonstrated that *EPO* overexpression in human islet cells provides protection from cell death²⁵. Studies in model organisms also suggest that *EPO* can protect against diabetes through a direct effect on β cells²⁶, and possibly through the modulation of glucose metabolism, glucose tolerance, and insulin sensitivity²⁷. Furthermore, Abhary and colleagues identified three genetic variants in *EPO* associated with a higher risk to develop diabetic retinopathy²⁸. Although no significant associations between *EPO* SNPs and T2D or its vascular complications were identified in our earlier analysis¹⁵, the findings in this study corroborate the close and complex link between erythropoietin and diabetes status.

A weakness of this study is that the specific causes of death were not determined during follow-up, preventing us from conducting an in-depth evaluation of the association of the investigated SNPs with the mortality risk in diabetic patients. Also, the mechanism through which the *EPO* TTA haplotype increases mortality in T2D patients is unknown at this time. However, it is important to point out that Tong and colleagues previously found that the *EPO* rs1617640-T allele is associated with a 25-fold higher promoter activity compared with the G allele, suggesting that this SNP plays a significant functional role in *EPO* expression²⁹. Taken together with our results this observation suggests that high levels of erythropoietin may have detrimental effects in patients with T2D.




Figure 1. Survival functions of carriers of minor allele (black) vs non carriers (grey) of *EPO* variants. (A) rs1617640; (B) rs507392; (C) rs551238. Time is expressed in years, where 0 is considered the time of recruitment. The Cox regression was adjusted for age, gender WHR, HbA1c, anaemia, diabetes duration, and diabetes complications. HR value, confidence interval, and p-value from Cox regression analysis are reported inside the figure.

This idea is supported by several pieces of evidence. Elevated erythropoietin concentrations have been linked to proliferative diabetic retinopathy, which in turn is associated with excessive vascular growth³⁰. A study by Wagner and colleagues also showed that in diabetic patients with CKD, elevated endogenous EPO levels were predictive of all-cause mortality and related mainly to markers of inflammation independently of kidney function and haemoglobin levels³¹. Similar results were observed in people aged 85 years and older³² and in patients with heart failure^{33,34}. Given that our analysis did not detect any correlation between the studied *EPO* SNPs and the presence/absence of anaemia (data not shown), it is plausible that inflammation, a key emerging risk factor for T2D, is a potential mechanism linking EPO and mortality in T2D patients.

It has been shown that EPO acts as a proliferative factor and thereby can promote tumor growth and metastasis³⁵. Ongoing studies indicate that the use of EPO for the treatment of cancer-induced anaemia is related to an increased incidence of cancer progression and reduced survival of patients³⁶. Epidemiologic evidence indicates




Figure 2. Survival functions of carriers (black) vs non carriers (grey) of the G-C-C haplotype of *EPO*. Time is expressed in years, where 0 is considered the time of recruitment. The Cox regression model was adjusted for age, gender WHR, HbA1c, anaemia, diabetes duration, and diabetes complications. HR value, confidence interval and p-value from Cox regression analysis are reported inside the figure.

that diabetes is associated with increased risk of many types of cancer³⁷; therefore, it is also possible that higher levels of *EPO* might contribute to the increased risk of mortality in diabetic patients because of an increased incidence of cancer. In this regard, it is notable that an *EPO* polymorphism (rs576236) in LD with those here investigated confers susceptibility to adrenal tumor³⁸.

In conclusion, this study identified an *EPO* haplotype that increases the risk of mortality among patients with T2D, independently of non-genetic risk factors. Over the last 30 years, it has become clear that erythropoietin possesses several tissue-specific functions that go far beyond the regulation of red cell production; therefore, further studies are needed to elucidate the molecular mechanisms linking *EPO* and mortality in diabetic patients. The elucidation of the mechanisms underlying the observed genetic associations could not only enhance our understanding of the molecular and genetic basis of the disease but also provide valuable insights into potential targets for therapeutic interventions aimed at increasing the survival of diabetic patients.

Methods

Study population and genetic data. Classification criteria and details of the cohort as well as the genetic data used in this study were previously reported¹⁵. Briefly, the sample includes 542 individuals with T2D (mean age 65.8 ± 8.0), collected by the Diabology Unit, INRCA (National Institute on Health and Science on Aging) in Ancona (Italy). Briefly, demographic, anthropometric and clinical data were collected for each individual and recorded in a well-defined questionnaire. The presence/absence of diabetic complications was evidenced as follows: diabetic retinopathy by fundoscopy through dilated pupils and/or fluorescence angiography; incipient nephropathy, defined as an urinary albumin excretion rate > 30 mg/24 h and a normal creatinine clearance; CKD, defined as an estimated glomerular filtration rate < 60 mL/min per 1.73 m²; neuropathy was established by electromyography.

Ethical approval for this study has been granted by the Ethics Committee of National Institute on Health and Science on Aging (INRCA). All participants gave written informed consent. All methods were performed in accordance with the relevant guidelines and regulations.

The genetic data includes 40 SNPs located in or near 21 candidate genes. However, nine SNPs were excluded from the analysis because they had either a high proportion of missing genotypes (call rate lower than 90%; rs669173, rs2853669, rs4880, rs13266634, rs7901695, rs8047395) or a minor allele frequency (MAF) lower than 5% (rs3811791, rs16889462, rs2237892). The final dataset included 31 high-quality SNPs that were tested for association with survival (see Supplementary Table S1).

Outcome. The main outcome of our study was all-cause mortality. The average follow-up duration was 12.08 years (range 1.41–13.66 years). At each follow-up visit, information was collected on vital status, functional status, and occurrence of diabetes complications. For patients who died during the follow-up period, information about date and place of death were collected from death certificates provided by relatives or caregivers. City or town registers were consulted to retrieve information about death when death certificates were not provided. After this period 61 men (20.5%) and 37 women (15.1%) died.

Analytic approach. Unpaired t-test and chi-square were performed for continuous and categorical variables, respectively, to compare variables and covariates between dead and survived patients at the end of the follow-up period. Cox regression models were used to evaluate the effect of anthropometric and haematological parameters, anaemia, diabetes duration, and diabetes complications on mortality. The length of survival from baseline visit until death was used as failure time for the models. Survivors were censored on the day of the last follow-up visit. The proportional hazard assumption was checked graphically, plotting the log-minus-log survival function over time. Kaplan-Meier analysis was performed to estimate survival curves stratified for each SNP. To control for the false-positive rate, the FDR method was used; the cut-off of the FDR adjusted p-value (q-value) was 0.10.

Covariates significantly associated with survival ($p < 0.05$) in the univariate analyses were included as confounding factors in the multivariate Cox proportional hazards models. These models were used to identify SNPs/haplotypes significantly associated with all-cause mortality. In all analyses, genetic data were coded using a dominant model (carriers for the minor allele versus non-carriers).

Pairwise measures of LD between the analyzed loci were calculated with the Haploview 4.2³⁹. The amount of LD was quantified by Lewontin's coefficient (D').

Statistical analyses were performed using the survival package of R v3.4.2 statistical language (R Foundation for Statistical Computing, Vienna, Austria, www.r-project.org).

Data Availability

The dataset analysed during the current study is available from the corresponding author on reasonable request.

References

- Zheng, Y., Ley, S. H. & Hu, F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol.* **14**, 88–98, <https://doi.org/10.1038/nrendo.2017.151> (2018).
- Bauduceau, B., Le Floch, J. P., Halimi, S., Verny, C. & Doucet, J. SFD/SFGG Intergroup. Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes. *Diabetes Care* **41**, 156–162, <https://doi.org/10.2337/dc17-1437> (2018).
- Jiang, Y. *et al.* Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies. *Eur J Epidemiol.* **26**, 863–876, <https://doi.org/10.1007/s10654-011-9617-y> (2011).
- Baena-Díez, J. M. *et al.* Risk of cause-specific death in individuals with diabetes: A competing risks analysis. *Diabetes Care* **39**, 1987–1995, <https://doi.org/10.2337/dc16-0614> (2016).
- Dunkley, A. *et al.* Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis. *Diabetes Care* **37**, 922–933, <https://doi.org/10.2337/dc13-2195> (2014).
- Chiang, H. H. *et al.* All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A1c, systolic blood pressure, and low-density lipoprotein cholesterol levels. *PLoS One* **9**, e109501, <https://doi.org/10.1371/journal.pone.0109501> (2014).
- Arnold, L. W. & Wang, Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is j-shaped: A meta-analysis of observational studies. *Rev Diabet Stud.* **11**, 138–152, <https://doi.org/10.1900/RDS.2014.11.138> (2014).
- Kontopantelis, E. *et al.* Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. *Diabetologia* **58**, 505–518, <https://doi.org/10.1007/s00125-014-3473-8> (2014).
- Hamada, S. & Gulliford, M. C. Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol. *J Am Geriatr Soc.* **64**, 1425–1431, <https://doi.org/10.1111/jgs.14215> (2016).
- Ali, O. Genetics of type 2 diabetes. *World J Diabetes* **4**, 114–123, <https://doi.org/10.4239/wjd.v4.i4.114> (2013).
- Ahlqvist, E., Van Zuydam, N. R., Groop, L. C. & McCarthy, M. I. The genetics of diabetic complications. *Nat Rev Nephrol.* **11**, 277–287, <https://doi.org/10.1038/nrneph.2015.37> (2015).
- Landman, G. W. D. *et al.* Association between 9p21 genetic variants and mortality risk in a prospective cohort of patients with type 2 diabetes (ZODIAC-15). *Cardiovasc Diabetol.* **11**, 138, <https://doi.org/10.1186/1475-2840-11-138> (2012).
- Prudente, S. *et al.* Genetic Variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. *Diabetes* **64**, 2658–2663, <https://doi.org/10.2337/db14-1653> (2015).
- Leong, A., Porneala, B., Dupuis, J., Florez, J. C. & Meigs, J. B. Type 2 diabetes genetic predisposition, obesity, and all-cause mortality risk in the U.S.: A multiethnic analysis. *Diabetes Care* **39**, 539–546, <https://doi.org/10.2337/dc15-2080> (2016).
- Montesanto, A. *et al.* Genes associated with Type 2 Diabetes and vascular complications. *Aging* **10**, 178–196, <https://doi.org/10.18632/aging.101375> (2018).
- Tancredi, M. *et al.* Excess Mortality among Persons with Type 2 Diabetes. *N Engl J Med.* **373**, 1720–1732, <https://doi.org/10.1056/NEJMoa1504347> (2015).
- Tönnies, T., Hoyer, A. & Brinks, R. Excess mortality for people diagnosed with type 2 diabetes in 2012 – Estimates based on claims data from 70 million Germans. *Nutr Met Cardiovasc Dis.* **28**, 887–891, <https://doi.org/10.1016/j.numecd.2018.05.008> (2018).
- McEwen, L. N. *et al.* Predictors of mortality over 8 years in type 2 diabetic patients: Translating research into action for diabetes (TRIAD). *Diabetes Care* **35**, 1301–1309, <https://doi.org/10.2337/dc11-2281> (2012).
- Bunn, H. F. Erythropoietin. *Cold Spring Harb Perspect Med.* **3**, a011619–a011619, <https://doi.org/10.1101/cshperspect.a011619> (2013).
- Lombardero, M., Kovacs, K. & Scheithauer, B. W. Erythropoietin: A hormone with multiple functions. *Pathobiology* **78**, 41–53, <https://doi.org/10.1159/000322975> (2011).
- Zhang, Y. *et al.* Erythropoietin action in stress response, tissue maintenance and metabolism. *Int J Mol Sci.* **15**, 10296–10333, <https://doi.org/10.3390/ijms150610296> (2014).
- Wang, L., Di, L. & Noguchi, C. T. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. *Int J Biol Sci.* **10**, 921–939, <https://doi.org/10.7150/ijbs.9518> (2014).
- Maiese, K., Chong, Z. Z., Shang, Y. C. & Wang, S. Erythropoietin: New directions for the nervous system. *Int J Mol Sci.* **13**, 11102–11129, <https://doi.org/10.3390/ijms130911102> (2012).
- Maiese, K. Erythropoietin and diabetes mellitus. *World J Diabetes* **6**, 1259–1273, <https://doi.org/10.4239/wjd.v6.i14.1259> (2015).
- Fenjves, E. S. *et al.* Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. *Transplantation* **77**, 13–18, <https://doi.org/10.1097/01.TP.0000110422.27977.26> (2004).
- Choi, D. *et al.* Erythropoietin protects against diabetes through direct effects on pancreatic β cells. *J Exp Med.* **207**, 2831–2842, <https://doi.org/10.1084/jem.20100665> (2010).
- Chen, L. N. *et al.* Erythropoietin improves glucose metabolism and pancreatic β -cell damage in experimental diabetic rats. *Mol Med Rep.* **12**, 5391–5398, <https://doi.org/10.3892/mmr.2015.4006> (2015).
- Abhary, S. *et al.* Association between erythropoietin gene polymorphisms and diabetic retinopathy. *Arch Ophthalmol.* **128**, 102–106, <https://doi.org/10.1001/archophthalmol.2009.355> (2010).
- Tong, Z. *et al.* Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. *PNAS* **105**, 6998–7003, <https://doi.org/10.1073/pnas.0800454105> (2008).
- Semeraro, F. *et al.* Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. *Diabetes Metab.* **40**, 445–451, <https://doi.org/10.1016/j.diabet.2014.04.005> (2014).
- Wagner, M. *et al.* Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. *Clin J Am Soc Nephrol.* **6**, 1573–1579, <https://doi.org/10.2215/CJN.00380111> (2011).
- Den Elzen, W. P. J. *et al.* Effect of erythropoietin levels on mortality in old age: The Leiden 85-plus study. *CMAJ.* **182**, 1953–1958, <https://doi.org/10.1503/cmaj.100374> (2010).

33. Belonje, A. M. S. *et al.* Endogenous erythropoietin and outcome in heart failure. *Circulation* **121**, 245–251, <https://doi.org/10.1161/CIRCULATIONAHA.108.844662> (2010).
34. Garimella, P. S. *et al.* Association of Serum Erythropoietin with Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study. *Circ Heart Fail.* **9**, e002124, <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002124> (2016).
35. Hedley, B. D., Allan, A. L. & Xenocostas, A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. *Clin Cancer Res.* **17**, 6373–6380, <https://doi.org/10.1158/1078-0432.CCR-10-2577> (2011).
36. Cao, Y. Erythropoietin in cancer: A dilemma in risk therapy. *Trends Endocrinol Metab.* **24**, 190–199, <https://doi.org/10.1016/j.tem.2012.10.007> (2013).
37. Giovannucci, E. *et al.* Diabetes and cancer: A consensus report. *Diabetes Care* **33**, 1674–1685, <https://doi.org/10.2337/dc10-0666> (2010).
38. Zhang, C. *et al.* Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. *J Biomed Res.* **28**, 456–461, <https://doi.org/10.7555/JBR.28.20130126> (2014).
39. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: Analysis and visualization of LD and haplotype maps. *Bioinformatics* **21**, 263–265, <https://doi.org/10.1093/bioinformatics/bth457> (2005).

Acknowledgements

This study was partially supported by Ricerca Corrente funding from Italian Ministry of Health to IRCCS INRCA, by “Ricerca scientifica di Ateneo” from UNIVPM to FO and by the Italian Ministry of University and Research (PRIN: Progetti di Ricerca di rilevante Interesse Nazionale – 2015, Prot. 20157ATSLF) to G.R. The work has been made possible by the collaboration with Gruppo Baffa (Sadel Spa, Sadel San Teodoro srl, Sadel CS srl, Casa di Cura Madonna dello Scoglio, AGI srl, Casa di Cura Villa del Rosario srl, Savelli Hospital srl, Casa di Cura Villa Ermelinda).

Author Contributions

F.O., R.T., A.R.B. and G.R. conceived the experiments; E.M., C.P., C.G. and P.G. conducted the experiments; A.M., P.C., and G.R. made statistical analyses; F.O., A.M., M.D.L. and G.R. analysed the data and wrote the manuscript; C.F., F.R., M.D.L. and G.P. made critical review. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-46894-2>.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019